Eli Lilly ( LLY -0.14%) is the most valuable healthcare stock in the world, with a market capitalization of nearly $700 ...

Eli Lilly’s strong position in GLP-1 drugs is overlooked by the market. Find out why LLY stock is a buy even as others pull ...

Data from a phase II study shows that AMGN's obesity drug MariTide leads to sustainable weight loss, robust improvements in ...

The Biden administration believes that including obesity drugs in Medicare coverage will reduce out-of-pocket costs for the ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

The stock's early-sessions lows when it was down more than ... That news sent the stocks of market leaders Novo Nordisk A/S (NVO) and Eli Lilly & Co. (LLY) higher, along with Viking Therapeutics Inc. ...

The stocks of companies that make the new class of drugs to treat obesity and manage diabetes were higher across the board ...

Pharmaceutical stocks make great additions to any portfolio in any market environment. A good one promises steady revenue ...

Shares in Danish drug maker Novo Nordisk have increased following President Biden's ... that Novo's share movement coincided with similar trends in the market, as Eli Lilly, a U.S. competitor, also ...

The Biden administration is proposing a rule that would require the U.S. government to cover weight-loss drugs, potentially expanding access for millions of Americans with obesity and creating ...

The company reported a Phase 2 study of its injectable MariTide medicine showed an approximately 20% average weight loss over one year for patients who were obese or overweight without diabetes. In ...

MariTide’s Phase 2 press release “underwhelms” with 20% weight loss from Cohort A and 17% weight loss from Cohort B at 52-weeks, with it being unclear if these are placebo adjusted. MariTide’s weight ...